Syphilis Testing: Use Both Test Types Together—Never Rely on One Alone
Both treponemal and non-treponemal tests must be used in combination for syphilis diagnosis, as using only one type is insufficient and can lead to false-positive results 1, 2. The specific algorithm you choose depends on your laboratory's capabilities and patient population.
Testing Algorithms: Three Approaches
Traditional Algorithm (Screen with Non-Treponemal First)
- Initial screening: RPR or VDRL (non-treponemal test)
- If reactive: Confirm with treponemal test (FTA-ABS, TP-PA, or TPPA)
- Major limitation: Misses early primary syphilis before antibody development and late/treated syphilis with low/negative non-treponemal titers 1, 3
- Sensitivity for clinical diagnosis: Only 41.9% 3
Reverse Sequence Algorithm (Screen with Treponemal First)
- Initial screening: Automated treponemal test (EIA or chemiluminescence immunoassay)
- If reactive: Perform quantitative non-treponemal test (RPR or VDRL)
- If non-treponemal negative: Run second, different treponemal test (preferably TP-PA)
- Performance: 100% sensitivity and specificity when compared to clinical diagnosis 2, 3
ECDC Algorithm (Preferred for High-Volume Labs)
- Initial screening: Treponemal test (TP-EIA or CIA)
- If reactive: Reflex to confirmatory treponemal test
- Performance: 100% sensitivity and specificity 3
- Advantage: Superior detection of latent syphilis cases 3
Critical Distinctions Between Test Types
Non-Treponemal Tests (RPR, VDRL)
- Purpose: Monitor disease activity and treatment response 1, 4
- Report quantitatively: Always include titers (e.g., 1:16,1:32)
- Significant change: Fourfold titer change (two dilutions) indicates clinical significance 1
- Use same method: Sequential tests must use identical methodology (RPR vs RPR, not RPR vs VDRL) by the same laboratory 1
- Pitfall: RPR titers run slightly higher than VDRL—cannot directly compare 1
- After treatment: Usually become non-reactive, but some patients remain "serofast" at low titers lifelong 1
Treponemal Tests (FTA-ABS, TP-PA, EIA, CIA)
- Purpose: Confirm infection—NOT for monitoring treatment 1, 5
- Remain positive: Stay reactive for life in most patients regardless of treatment 1
- Exception: 15-25% of primary stage patients revert to negative after 2-3 years 1
- Do not use titers: Treponemal antibody levels correlate poorly with disease activity 1
Monitoring Treatment Response
Use only non-treponemal tests (RPR or VDRL) quantitatively 1, 4:
- Fourfold decrease in titer = adequate response (e.g., 1:32 → 1:8)
- Same test method at same laboratory for all follow-up
- Treponemal tests are useless for monitoring—they stay positive 1
Special Populations
HIV-Infected Patients
- Serologic tests remain accurate for most HIV patients 1
- Watch for: Atypical results (unusually high, low, or fluctuating titers)
- If discordant: Consider biopsy and direct microscopy when serology doesn't match clinical picture 1
Neurosyphilis Evaluation
- CSF testing: VDRL-CSF only (not RPR on CSF) 6
- VDRL-CSF: Highly specific but insensitive—reactive result is diagnostic 1
- CSF FTA-ABS: More sensitive but less specific—negative result may exclude neurosyphilis 1, 5
- No single test diagnoses neurosyphilis—combine serology, CSF cell count, protein, and clinical findings 1
Common Pitfalls to Avoid
Never diagnose with one test type alone—false positives occur with non-treponemal tests in various medical conditions 1
Don't use treponemal tests for treatment monitoring—they remain positive despite cure 1
Don't mix test methods—switching between RPR and VDRL invalidates titer comparisons 1
Don't ignore the "serofast" phenomenon—persistent low non-treponemal titers don't always mean treatment failure 1
Traditional algorithm misses cases—particularly latent syphilis; reverse/ECDC algorithms demonstrate superior diagnostic performance 3
Practical Recommendation
For laboratories with automated platforms: Use reverse sequence or ECDC algorithm starting with treponemal screening 2, 3. These algorithms achieve 100% sensitivity and specificity versus 41.9% for traditional screening, particularly excelling at detecting latent syphilis 3. Reserve non-treponemal tests exclusively for assessing disease activity and monitoring treatment response 3, 7.